Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453719 | PMC |
| http://dx.doi.org/10.1111/pai.13519 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bradykinin B receptor blockade and intradialytic hypotension.
BMC Nephrol
May 2023
Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, 2222 Pierce Avenue 561B-PRB, Nashville, TN, 37232-6602, USA.
Introduction: Intradialytic hypotension (IDH) is a common clinical complication and is associated with increased morbidity and mortality in patients undergoing maintenance hemodialysis (MHD). The pathogenesis of IDH has been attributed to the rapid reduction of plasma volume during hemodialysis and the inadequate compensatory mechanisms in response to hypovolemia, such as the lack of vasoconstriction. This may be due to the increased production of vasodilators, such as bradykinin.
View Article and Find Full Text PDFIs Icatibant Safe for the Treatment of Hereditary Angioedema During Pregnancy?
Curr Allergy Asthma Rep
October 2022
Department of Rheumatology and Clinical Immunology, Clinical Hospital Center Rijeka, Tome Strižića 3, 51000, Rijeka, Croatia.
Purpose Of Review: Hereditary angioedema (HAE) is a disorder affecting bradykinin regulation presenting as recurrent cutaneous or mucosal swelling. Treatment options include plasma-derived or human-recombinant C1-inhibitor, icatibant, or ecallantide. Due to the lack of knowledge and experience on the topic, the treatment of choice in pregnancy is plasma-derived C1-inhibitor, and reporting any new experience is recommended.
View Article and Find Full Text PDFVariability of disease activity in patients with hereditary angioedema type 1/2: longitudinal data from the Icatibant Outcome Survey.
J Eur Acad Dermatol Venereol
December 2021
Formerly Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Background: Hereditary angioedema due to C1 inhibitor deficiency (HAE-1/2) is a chronic and debilitating disease. The unpredictable clinical course represents a significant patient burden.
Objective: To analyse longitudinal registry data from the Icatibant Outcome Survey (IOS) in order to characterize temporal changes in disease activity in patients with HAE-1/2.
Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema.
Pediatr Allergy Immunol
August 2021
Department of Dermatology, Medical University of Graz, Graz, Austria.
Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks.
Allergol Int
January 2021
Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Hyogo, Japan.
Hereditary angioedema (HAE) is characterized by unpredictable, recurring and painful swelling episodes that can be disabling or even life-threatening. Awareness of HAE has progressively grown worldwide, and options for treatment of acute attacks and prevention of future attacks continue to expand; however, unmet needs in diagnosis and treatment remain. In Japan, recognition of HAE within the medical community remains low, and numerous obstacles complicate diagnosis and access to treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!